Gregory M. Sullivan

CIK: 0001610106

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TNXP

Tonix Pharmaceuticals Holding Corp.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 24, 2026
Award(A)
Stock Option
Direct
39K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 24, 2026
Award(A)
Stock Option
Direct
39K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 25, 2025
Award(A)
Stock Option
Direct
29K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 25, 2025
Award(A)
Stock Option
Direct
29K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Feb 5, 2025
Other(J)
Direct
0 shares at avg. $1.47$0.162

		Type	Shares	Price		Ownership
Feb 24, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	39,012	-	-	Direct
Feb 24, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	39,011	-	-	Direct
Feb 25, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	29,017	-	-	Direct
Feb 25, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	29,017	-	-	Direct
Feb 5, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Other(J)	0	$1.47	$0	Direct

1-5 of 5 transactions

About SULLIVAN GREGORY M

SULLIVAN GREGORY M (SEC CIK 0001610106) files insider reports with the SEC as Chief Medical Officer of Tonix Pharmaceuticals Holding Corp. (TNXP).

Signal8 holds 2 ownership filings by SULLIVAN GREGORY M, all Form 4s, filed between Feb 27, 2025 and Feb 26, 2026. Those filings report 5 transactions, from Feb 5, 2025 to Feb 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SULLIVAN GREGORY M's filings is in BERKLEY HEIGHTS, NJ.

Recent filings by SULLIVAN GREGORY M

Feb 24, 2026: Grants or awards of TNXP derivative securities (2 lines, Form 4, code A).
Feb 25, 2025: Grants or awards of TNXP derivative securities (2 lines, Form 4, code A).
Feb 5, 2025: Other transaction of TNXP shares (Form 4, code J).

Other insiders filing for Tonix Pharmaceuticals Holding Corp. (TNXP)

Englese Thomas, Chief Commercial Officer
BAGGER RICHARD H, Director
SAENGER BRADLEY, Chief Financial Officer
Taylor Carolyn E., Director
Stillwell Richard Newcomb, Director
LEDERMAN SETH, Chief Executive Officer

How to read Form 4 transaction codes